NASDAQ:INDP Indaptus Therapeutics (INDP) Stock Price, News & Analysis $2.52 +0.15 (+6.33%) As of 01:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Indaptus Therapeutics Stock (NASDAQ:INDP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Indaptus Therapeutics alerts:Sign Up Key Stats Today's Range$2.31▼$2.5950-Day Range$2.28▼$12.5852-Week Range$2.22▼$58.24Volume226,547 shsAverage Volume115,091 shsMarket Capitalization$2.80 millionP/E RatioN/ADividend YieldN/APrice Target$238.00Consensus RatingBuy Company Overview Indaptus Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease. Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors. The company is also exploring applications in antiviral immunotherapies, reflecting the versatility of its platform. By combining advanced engineering techniques with scalable manufacturing processes, Indaptus aims to deliver off-the-shelf therapies to patients with unmet medical needs. Headquartered in the United States, Indaptus collaborates with academic institutions and contract research organizations to advance discovery and clinical translation. Since its inception, the company has established state-of-the-art research and development facilities to support process development, preclinical evaluation, and future clinical manufacturing. Led by a management team with deep experience in cell and gene therapy development, Indaptus is positioned to move its lead programs into early-phase clinical trials and expand its strategic partnerships in the biopharmaceutical industry.AI Generated. May Contain Errors. Read More Indaptus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreINDP MarketRank™: Indaptus Therapeutics scored higher than 69% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIndaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialIndaptus Therapeutics has a consensus price target of $238.00, representing about 9,674.1% upside from its current price of $2.44.Amount of Analyst CoverageIndaptus Therapeutics has received no research coverage in the past 90 days.Read more about Indaptus Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indaptus Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indaptus Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIndaptus Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Indaptus Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.51% of the float of Indaptus Therapeutics has been sold short.Short Interest Ratio / Days to CoverIndaptus Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indaptus Therapeutics has recently decreased by 19.25%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIndaptus Therapeutics does not currently pay a dividend.Dividend GrowthIndaptus Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.51% of the float of Indaptus Therapeutics has been sold short.Short Interest Ratio / Days to CoverIndaptus Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indaptus Therapeutics has recently decreased by 19.25%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentIndaptus Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.MarketBeat Follows2 people have added Indaptus Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.80% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.06% of the stock of Indaptus Therapeutics is held by institutions.Read more about Indaptus Therapeutics' insider trading history. Receive INDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INDP Stock News HeadlinesIndaptus Therapeutics stock falls after mixed clinical trial updatesSeptember 6, 2025 | za.investing.comIndaptus Therapeutics provides update on INDP-D101 clinical trialSeptember 5, 2025 | msn.comCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really investing in this coin.September 18 at 2:00 AM | Crypto 101 Media (Ad)Indaptus Therapeutics Reports Positive Monotherapy Results for Decoy20 in Urothelial Cancer, Initiates Combination Therapy with TislelizumabSeptember 4, 2025 | quiverquant.comQIndaptus Therapeutics Provides Clinical UpdateSeptember 4, 2025 | globenewswire.comIndaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comIndaptus Therapeutics files $200M mixed securities shelfAugust 14, 2025 | msn.comIndaptus Therapeutics reports Q2 EPS ($9.09) vs ($13.16) last yearAugust 13, 2025 | msn.comSee More Headlines INDP Stock Analysis - Frequently Asked Questions How have INDP shares performed this year? Indaptus Therapeutics' stock was trading at $23.5788 at the start of the year. Since then, INDP stock has decreased by 89.7% and is now trading at $2.4350. How were Indaptus Therapeutics' earnings last quarter? Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced its quarterly earnings data on Wednesday, August, 13th. The company reported ($9.09) EPS for the quarter, missing the consensus estimate of ($0.36) by $8.73. When did Indaptus Therapeutics' stock split? Indaptus Therapeutics shares reverse split on Friday, June 27th 2025.A 1-28 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Indaptus Therapeutics? Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Indaptus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Indaptus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), GE Aerospace (GE), Meta Platforms (META), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/13/2025Today9/18/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INDP CIK1857044 Webintecpharma.com Phone(646) 427-2727Fax972-2586-9176Employees6Year FoundedN/APrice Target and Rating Average Price Target for Indaptus Therapeutics$238.00 High Price Target$336.00 Low Price Target$140.00 Potential Upside/Downside+9,942.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($37.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.02 million Net MarginsN/A Pretax MarginN/A Return on Equity-612.59% Return on Assets-243.78% Debt Debt-to-Equity RatioN/A Current Ratio0.75 Quick Ratio0.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.84 per share Price / Book0.22Miscellaneous Outstanding Shares1,110,000Free Float877,000Market Cap$2.63 million OptionableNot Optionable Beta1.27 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:INDP) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.